1.Oral Arsenic-Containing Qinghuang Powder: A Potential Drug for Myelodysplastic Syndromes.
Jing MING ; Wei-Yi LIU ; Hai-Yan XIAO ; Yong-Gang XU ; Rou MA ; Xiao-Mei HU
Chinese journal of integrative medicine 2022;28(8):762-768
Qinghuang Powder (QHP), an oral arsenic, has become an effective drug in the treatment of myelodysplastic syndromes (MDS) in Xiyuan Hospital, China Academy of Chinese Medical Sciences for many years, and the action mechanism of the compound or active ingredient As2S2 of QHP has been elucidated. Considering the relatively safety, chemotherapy-free and convenient oral profile, QHP is widely used in the clinical treatment for MDS patients, especially for elderly patients. In this review, the authors document the efficacy and safety of oral arsenic-containing compound QHP in the treatment of MDS, with a special focus on the association of efficacy of QHP with the cytogenetics, prognostic risk, DNA methylation, gene mutation, blood arsenic concentration, mechanism of action of As2S2 and the countermeasures against adverse reactions of gastrointestinal tract.
Aged
;
Arsenic/therapeutic use*
;
Arsenicals/adverse effects*
;
Drugs, Chinese Herbal
;
Humans
;
Myelodysplastic Syndromes/genetics*
;
Powders/therapeutic use*
2.Application of Chinese patent medicines for external-contraction febrile disease in Medical Records Integration of Palace in Qing Dynasty.
Kam-Ping LEUNG ; Yong-Kuan JI ; Guo-Sen CHEN ; Guo LIU
China Journal of Chinese Materia Medica 2022;47(20):5662-5669
Medical records in the treatment of external-contraction febrile diseases with Chinese patent medicines in Medical Records Integration of Palace in Qing Dynasty were collected and the syndromes of the diseases, and types, categories, and dosage forms of the medicines were summarized to analyze the use of Chinese patent medicines for the external-contraction febrile diseases. The incidence of the diseases is closely related to the constitution, dietary habit, and emotion of patients. Therefore, the diseases were mainly manifested as cold, warm disease in summer, and summerheat-caused affection, and they were also attributed to the internal causes such as dampness, indigestion, phlegm, and stagnated heat. Thus, heat-clearing and summerheat-expelling formulas represented by Yiyuan Powder and Liuyi Powder were most frequently used, followed by the formulas for promoting digestion and removing food stagnation and formulas of ophthalmology and otorhinolaryngology and surgery department. The composition and application of the most common Chinese patent medicines were analyzed, and the medicines which were also recorded in Chinese Pharmacopoeia(2020) were selected for further comparison to provide a reference for the current application of them. In the development of Chinese patent medicines, the influence of the processing on the efficacy should be emphasized and the application value of classical prescriptions should be further explored. It is of great significance for the composition optimization and efficacy improvement of modern Chinese patent medicines to study the compatibility of mineral medicinals in traditional formulas. When it comes to application in clinical settings, the indications, usage, and application modes of the Chinese patent medicines of Qing Dynasty are of reference value for modern application. Moreover, the anti-epidemic policies and anti-epidemic tea drinks in the records can serve as a reference for the prevention and control of pestilence diseases at present.
Humans
;
Medicine, Chinese Traditional
;
Nonprescription Drugs
;
Drugs, Chinese Herbal/therapeutic use*
;
Powders
;
Medical Records
;
China
3.Clinical efficacy of adaptive biofeedback training combined with oral administration of compound polyethylene glycol 4000-electrolyte powder in the treatment of children with outlet obstruction constipation: a prospective randomized controlled trial.
Rui-Feng WANG ; Fang ZHOU ; Huan WANG ; Zhi-Dan YU ; Xiao-Qin LI
Chinese Journal of Contemporary Pediatrics 2022;24(4):377-381
OBJECTIVES:
To study the clinical efficacy, advantages, and disadvantages of adaptive biofeedback training combined with oral administration of compound polyethylene glycol 4000-electrolyte powder in the treatment of children with outlet obstruction constipation (OOC).
METHODS:
A total of 168 children with OOC were enrolled in this prospective study. All the subjects were randomly divided into a test group and a control group based on the order of visiting time, 84 in each group. The test group was treated with adaptive biofeedback training combined with oral administration of compound polyethylene glycol 4000-electrolyte powder, and the control group was treated with oral administration of compound polyethylene glycol 4000-electrolyte powder alone. Eleven children in the test group and two children in the control group withdrew from the study since they could not finish the whole treatment course. Finally, 73 children in the test group and 82 children in the control group were included in this analysis. As clinical outcomes, the total score of clinical symptoms and overall response rate were compared between the two groups at weeks 4 and 8 of treatment.
RESULTS:
There was no significant difference in the total score of clinical symptoms between the two groups at beginning of treatment and at week 4 (P>0.05), while the test group had a significantly lower total score of clinical symptoms than the control group at week 8 (P<0.05). At week 4, there was no significant difference in overall response rate between the two groups (P>0.05), while the test group had a significantly higher overall response rate than the control group at week 8 (P<0.05).
CONCLUSIONS
Adaptive biofeedback training combined with oral administration of compound polyethylene glycol 4000-electrolyte powder is significantly associated with improvement of clinical outcomes in the treatment of children with OOC.
Administration, Oral
;
Biofeedback, Psychology
;
Child
;
Constipation/drug therapy*
;
Electrolytes/therapeutic use*
;
Humans
;
Polyethylene Glycols/therapeutic use*
;
Powders/therapeutic use*
;
Prospective Studies
;
Treatment Outcome
4.Comparing Arsenic-Containing Qinghuang Powder and Low-Intensity Chemotherapy in Elderly Patients with Acute Myeloid Leukemia.
Yu-He WU ; Hai-Yan XIAO ; Ri-Cheng QUAN ; Xu-Dong TANG ; Wei-Yi LIU ; Yan LYU ; Zhuo CHEN ; Chi LIU ; Xiao-Mei HU
Chinese journal of integrative medicine 2023;29(9):832-837
OBJECTIVE:
To compare the clinical effect of arsenic-containing Qinghuang Powder (QHP) and low-intensity chemotherapy (LIC) in treatment of elderly acute myeloid leukemia (eAML) patients.
METHODS:
Clinical data of 80 eAML patients treated at Xiyuan Hospital of China Academy of Chinese Medical Sciences from January 2015 to December 2020 were retrospectively analyzed. The treatment scheme was designed by real world study according to patients' preference, and patients were divided into a QHP group (35 cases) and a LIC group (45 cases). The median overall survival (mOS), 1-, 2-, and 3-year OS rates, and incidence of adverse events were compared between the two groups.
RESULTS:
The mOS of 80 patients was 11 months, and the 1-, 2-, and 3-year OS rates were 45.51%, 17.96%, and 11.05%, respectively. The QHP and LIC groups demonstrated no significant difference in mOS (12 months vs. 10 months), 1- (48.57% vs. 39.65%), 2- (11.43% vs. 20.04%), and 3-year OS rates (5.71% vs. 13.27%, all P>0.05). Moreover, the related factors of mOS demonstrated no significant difference in patients with age>75 years (11 months vs. 8 months), secondary AML (11 months vs. 8 months), poor genetic prognosis (9 months vs. 7 months), Eastern Cooperative Oncology Group performance status score ⩾ 3 (10 months vs. 7 months) and hematopoietic stem cell transplant comorbidity index ⩾ 4 (11 months vs. 7 months) between the QHP and LIC groups (all P>0.05). However, the incidence of myelosuppression was significantly lower in the QHP group than that in the LIC group (28.57% vs. 73.33%, P<0.01).
CONCLUSIONS
QHP and LIC had similar survival rates in eAML patients, but QHP had a lower myelosuppression incidence. Hence, QHP can be an alternative for eAML patients who do not tolerate LIC.
Humans
;
Aged
;
Arsenic/therapeutic use*
;
Powders/therapeutic use*
;
Retrospective Studies
;
Leukemia, Myeloid, Acute/drug therapy*
;
Prognosis
;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*
6.Clinical observation on treatment of 107 patients with fatty liver by jinchan shugan powder.
Song-ming ZHENG ; Jing-jing ZHENG
Chinese Journal of Integrated Traditional and Western Medicine 2003;23(12):929-930
Adult
;
Drug Combinations
;
Drugs, Chinese Herbal
;
therapeutic use
;
Fatty Liver
;
drug therapy
;
Female
;
Humans
;
Male
;
Middle Aged
;
Phytotherapy
;
Powders
7.Morphological observation on gastric mucosa membrane of patients with gastric ulcer treated with combined use of Qifang Weitong Powder and omeprazole.
Chang DENG ; Wei-sheng LUO ; Gui-xian LI
Chinese Journal of Integrated Traditional and Western Medicine 2007;27(7):610-612
OBJECTIVETo observe the histological changes of gastric mucosa in patients with active gastric ulcer before and after treatment by Qifang Weitong Powder combined with omeprazole (QWP-Op).
METHODSSixty patients were equally randomized into the treated group and the control group. They were all treated in the 1st week by the Helicobacter pylori eradication triad regimen. From the 2nd to 6th week, the study group re-ceived QWP-Op therapy, and the control group was given Omeprazole alone.Biopsy specimens were obtained around ulcer area before and after treatment for histological observation on changes of gastric mucosa membrane.
RESULTSThe improvement of mucosal thickness and glandular morphology was better in the treated group than that in the control group (P <0.05).
CONCLUSIONQWP-Op therapy can improve the histological quality of ulcer healing and restore the morphological structure of gastric mucosa in patients with active gastric ulcer.
Adult ; Anti-Ulcer Agents ; therapeutic use ; Biopsy, Needle ; Drug Therapy, Combination ; Drugs, Chinese Herbal ; therapeutic use ; Female ; Gastric Mucosa ; pathology ; Humans ; Male ; Middle Aged ; Omeprazole ; therapeutic use ; Phytotherapy ; Powders ; Stomach Ulcer ; drug therapy ; pathology ; Treatment Outcome ; Young Adult
8.Clinical observation on xiehuo yangyin powder in treating 30 initial stage of toxic and diffuse goiter patients.
Xue-mei LI ; Yong-fen CAO ; Juan YANG
Chinese Journal of Integrated Traditional and Western Medicine 2003;23(11):829-831
OBJECTIVETo observe the therapeutic effect of Xiehuo Yangyin powder (XHYY) in treating the initial stage of toxic and diffuse goiter (Graves' disease).
METHODSSixty patients were randomly divided into two groups, the treated group (n = 30) was treated with XHYY and methimazole, while the control group (n = 30) was treated with methimazole alone. The TCM syndrome score and thyroxin level in the two groups were compared and analyzed before, and 2 weeks, 12 weeks after treatment.
RESULTSThe syndrome score and thyroxin level in the treated group 2 weeks, 4 weeks, 12 weeks after treatment were reduced in comparing with before treatment, with the improvement better than those in the control group in the corresponding stages (P < 0.05).
CONCLUSIONThe Chinese herbal medicine XHYY plus methimazole, in treating Graves' disease, could rapidly and effectively improve the patients' clinical symptoms and lower the thyroxin level, reduce the daily taken of methimazole.
Adolescent ; Adult ; Aged ; Antithyroid Agents ; therapeutic use ; Drug Therapy, Combination ; Drugs, Chinese Herbal ; therapeutic use ; Female ; Graves Disease ; blood ; drug therapy ; Humans ; Male ; Methimazole ; therapeutic use ; Middle Aged ; Phytotherapy ; Powders ; Thyroxine ; blood
9.Effect of modified chaihu shugan powder in treating patients with functional dyspepsia accompanied with depression.
Cheng-Er ZHAN ; Jian-Yong CHEN ; Feng PAN
Chinese Journal of Integrated Traditional and Western Medicine 2004;24(12):1119-1121
Adult
;
Antidepressive Agents
;
therapeutic use
;
Depression
;
complications
;
drug therapy
;
Drugs, Chinese Herbal
;
therapeutic use
;
Dyspepsia
;
drug therapy
;
psychology
;
Female
;
Gastric Emptying
;
drug effects
;
Gastrointestinal Agents
;
therapeutic use
;
Gastrointestinal Motility
;
drug effects
;
Humans
;
Male
;
Middle Aged
;
Phytotherapy
;
Powders
10.Arsenic-Containing Qinghuang Powder () is an Alternative Treatment for Elderly Acute Myeloid Leukemia Patients Refusing Low-Intensity Chemotherapy.
Teng FAN ; Ri-Cheng QUAN ; Wei-Yi LIU ; Hai-Yan XIAO ; Xu-Dong TANG ; Chi LIU ; Liu LI ; Yan LV ; Hong-Zhi WANG ; Yong-Gang XU ; Xiao-Qing GUO ; Xiao-Mei HU
Chinese journal of integrative medicine 2020;26(5):339-344
OBJECTIVE:
To analyze the overall survival (OS) of elderly acute myeloid leukemia (AML) patients treated with oral arsenic-containing Qinghuang Powder (, QHP) or low-intensity chemotherapy (LIC).
METHODS:
Forty-two elderly AML patients treated with intravenous or subcutaneous LIC (1 month for each course, at least 3 courses) or oral QHP (3 months for each course, at least 2 courses) were retrospectively analyzed from January 2015 to December 2017. The main endpoints of analysis were OS and 1-, 2-, 3-year OS rates of patients, respectively. And the adverse reactions induding bone marrow suppression, digestive tract discomfort and myocardia injury were observed.
RESULTS:
Out of 42 elderly AML patients, 22 received LIC treatment and 20 received QHP treatment, according to patients' preference. There was no significant difference on OS between LIC and QHP patients (13.0 months vs. 13.5 months, >0.05). There was no significant difference on OS rates between LIC and QHP groups at 1 year (59.1% vs. 70.0%), 2 years (13.6% vs. 15%), and 3 years (4.6% vs. 5.0%, all >0.05). Furthermore, there was no significant difference of OS on prognosis stratification of performance status > 2 (12 months vs. 12 months), age> 75 year-old (12.0 months vs. 12.5 months), hematopoietic stem cell transplant comorbidity index >2 (12 months vs. 13 months), poor cytogenetics (12 months vs. 8 months), and diagnosis of secondary AML (10 months vs. 14 months) between LIC and QHP patients (>0.05).
CONCLUSION
QHP may be an alternative treatment for elderly AML patients refusing LIC therapy.
Aged
;
Aged, 80 and over
;
Antineoplastic Agents
;
therapeutic use
;
Arsenicals
;
therapeutic use
;
Drugs, Chinese Herbal
;
therapeutic use
;
Female
;
Humans
;
Leukemia, Myeloid, Acute
;
drug therapy
;
mortality
;
Male
;
Middle Aged
;
Powders
;
Retrospective Studies